Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration

CIF Janssen, AJ Kiliaan - Progress in lipid research, 2014 - Elsevier
Many clinical and animal studies demonstrate the importance of long-chain polyunsaturated
fatty acids (LCPUFA) in neural development and neurodegeneration. This review will focus …

Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity

SE Kanoski, TL Davidson - Physiology & behavior, 2011 - Elsevier
Intake of saturated fats and simple carbohydrates, two of the primary components of a
modern Western diet, is linked with the development of obesity and Alzheimer's Disease …

[HTML][HTML] Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

IC Arellanes, N Choe, V Solomon, X He, B Kavin… - …, 2020 - thelancet.com
Background Past clinical trials of docosahexaenoic Acid (DHA) supplements for the
prevention of Alzheimer's disease (AD) dementia have used lower doses and have been …

Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer's disease

V Rudajev, J Novotny - Frontiers in molecular neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is a neurodegenerative disorder that is one of the most
devastating and widespread diseases worldwide, mainly affecting the aging population. One …

[HTML][HTML] Omega-3 fatty acids and mental health

KW Lange - Global Health Journal, 2020 - Elsevier
Nutrition plays a key role in brain development, mental health, and psychiatric disorders.
The role of omega-3 polyunsaturated fatty acids in physical health is well established, and …

Nutrition and the Risk of Alzheimer′ s Disease

N Hu, JT Yu, L Tan, YL Wang, L Sun… - BioMed research …, 2013 - Wiley Online Library
Alzheimer′ s disease (AD) is a progressive neurodegenerative disorder that accounts for
the major cause of dementia, and the increasing worldwide prevalence of AD is a major …

Gut microbiome-targeted therapies for Alzheimer's disease

T Zhang, G Gao, LY Kwok, Z Sun - Gut microbes, 2023 - Taylor & Francis
The advent of highthroughput 'omics' technologies has improved our knowledge of gut
microbiome in human health and disease, including Alzheimer's disease (AD), a …

Oxidized cholesterol as the driving force behind the development of Alzheimer's disease

P Gamba, G Testa, S Gargiulo, E Staurenghi… - Frontiers in aging …, 2015 - frontiersin.org
Alzheimer's disease (AD), the most common neurodegenerative disorder associated with
dementia, is typified by the pathological accumulation of amyloid Aβ peptides and …

Causes and consequences of baseline cerebral blood flow reductions in Alzheimer's disease

O Bracko, JC Cruz Hernández, L Park… - Journal of Cerebral …, 2021 - journals.sagepub.com
Reductions of baseline cerebral blood flow (CBF) of∼ 10–20% are a common symptom of
Alzheimer's disease (AD) that appear early in disease progression and correlate with the …

Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers: a review

HN Yassine, MN Braskie, WJ Mack, KJ Castor… - JAMA …, 2017 - jamanetwork.com
Importance The apolipoprotein E ε4 (APOE4) allele identifies a unique population that is at
significant risk for developing Alzheimer disease (AD). Docosahexaenoic acid (DHA) is an …